TGFB1 and neoplasm: High expression levels of TGF-β ligand TGFB1 and its receptor TGFBR2, two crucial genes of the TGF-β signaling pathway, are associated with non-response and decreased OS in tumor patients treated with ICI immunotherapy (67).